ResMed Inc (ASX: RMD) – Full year and Fourth quarter result of FY18

Resmed

ResMed’s revenue (ASX: RMD) for the year was up 13% to US$2.3 billion while the group witnessed some impact from the US tax reforms. Up by 10 percent on a constant currency basis, the revenue of the firm surged up to $623.6 million for the fourth quarter of FY18. Net income increased by 8 percent while the non-GAAP net income is up by 24 percent. Research and development expenses were 6.4 percent of revenue or $39.7 million.

GAAP diluted earnings per share of $0.76 and non-GAAP diluted earnings per share of $0.95 were noted. In the fourth quarter, operating cash flow of $129.4 million was noted. Company’s quarterly dividend increased by 6 percent to $0.37 per share. Lower than the prior year’s quarter gross margin of 58.2 percent primarily due to declines in average selling prices, gross margin in the fourth quarter was 58.1 percent.

The stock of ResMed Inc traded at a market price of $14.470 as at August 3, 2018 and the stock has seen a performance change of 58.07% over the past 12 months.

Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

Sponsored ad by Kalkine

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


Disclaimer

The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.


6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report

LEAVE A REPLY

Please enter your comment!
Please enter your name here